Emerging data suggests that retatrutide, a dual-action medication, might represent a significant improvement in size loss . This therapy combines the effects of a GLP-1 receptor and a GIP receptor , possibly offering a enhanced benefit than available solutions. Clinical research have shown promising outcomes, including significant reductions in bo